Researchers utilize 3D printing to craft cerebral cortex tissues with organized neurons, offering potential treatments for brain injuries. This novel technique prints neural progenitors in layer-by-layer sequences, aiming for accurate tissue restoration in damaged brains.
Gilead’s newest acquisition: a liver disease drug with $1B in peak sales potential
Gilead’s acquisition of CymaBay Therapeutics underscores the company’s historic success in liver diseases and could bring in $1 billion in peak annual sales. Gilead announced
February 13, 2024